Public Company

ALX Oncology

ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.


ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.


Founded 2015
Type Public
Longevity related Yes
Location South San Francisco, California, USA

Recent Jobs at ALX Oncology

Latest News